OBJECTIVES: LUTS (lower urinary tract symptoms) are highly frequent and bothersome to the patient. Nocturia, defined by the International Continence Society as ‘waking to void 1 or more times a night followed by sleep’, is reported as being the most bothersome of these symptoms. The most frequent cause of nocturia is nocturnal polyuria (NP, overproduction of urine during the night defined as ≥33% of total urine volume). While there are well-known negative effects of nocturia on Health-related Quality of Life, there is limited information on the relationship between NP disease severity, as defined by the number of nightly voids, and utility. METHODS: Data were drawn from a randomised clinical trial of desmopressin (an antidiuretic) combined with tolterodine (an antimuscarinic agent) in women with overactive bladder and nocturia (ClinTrials.gov identifier: NCT01729819). Patients were required to have 2 or more nightly voids to be included in the trial, as this has been shown to be a clinically-relevant threshold for patient bother. We selected the subgroup of patients with NP who completed the Nocturia Impact Diary (a disease-specific HRQoL instrument, ranging from 0-100 where low values imply better QoL) and the generic EQ-5D-5L (n=41). The utility analysis was adjusted for age, body mass index, baseline number of nightly voids and number of comorbidities. RESULTS: The adjusted mean EQ-5D index for 2-3 voids was 0.87 and for 4 or more nightly voids 0.83 (ns). The adjusted EQ-5D VAS values were similar at 80.5 and 80.6. Unadjusted index utility values were 0.88 and 0.81, respectively. The Nocturia Impact Diary total scores were 41.5 and 46.8 for the two groups, respectively. CONCLUSIONS: The general disadvantage of the EQ-5D is that it is relatively insensitive to urinary diseases. This analysis suggests, however, that there is a relationship between nocturnal polyuria (and nocturia) disease severity, HRQoL and utility.